At the last SEC meeting, I raised some issues about Annotations that I’ve tried pull together at this Confluence page
There are some potential non-breaking changes to ADL/AOM documentation and potentially spec but they relate only to tooling, and not to CDRs, However they are causing issues for clinical modelling esp loss of support for multi-lingual annotations, which is problematic for some PROMS scores.
There are probably some easy-ish tooling / .opt / web template generation fixes in the short term.
I now realise that some of the design decisions in AD’s way of handling annotations in .opt is a consequence of trying to move to ADL2 path-based annotations but in doing so, running into 14 opt constraints.
The changes in AD that I think would fix this and give a more tolerable transition path are
Retain terminology-based annotations in .opt1.4 (remove in .opt2)
Support multilingual annotations in web templates
I don’t think either have an immediate impact on CKM .opt generation